{"nctId":"NCT02549352","briefTitle":"Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up","startDateStruct":{"date":"2015-11"},"conditions":["Actinic Keratosis"],"count":391,"armGroups":[{"label":"LEO 43204 gel","type":"EXPERIMENTAL","interventionNames":["Drug: LEO43204 gel"]},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle gel"]}],"interventions":[{"name":"LEO43204 gel","otherNames":["Ingenol Disoxate"]},{"name":"Vehicle gel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment area of sun-damaged skin on the full balding scalp (the balding part of the scalp should be greater than 25 cm2 (4 in2) and up to approximately 250 cm2 (40 In2)\n* Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking area of 50 cm2 (8 In2). The tracking area must be within the treatment area\n\nExclusion Criteria:\n\n* Location of the treatment area (balding scalp) within 5 cm of an incompletely healed wound or within 5 cm of a suspected BCC or SCC\n* Treatment with ingenol mebutate gel in the treatment area within the last 12 months\n* Lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions)\n* History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g. eczema, unstable psoriasis, xeroderma pigmentosum)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Complete Clearance of Actinic Keratosis (AK)","description":"The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1 (baseline), Weeks 4, and 8.\n\nComplete clearance was defined as no clinically visible AKs in the treatment area.\n\nThe table shows the percentage of mean number of participants across imputations with complete clearance at Week 8.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Clearance","description":"The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.\n\nPartial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.\n\nThe table shows the percentage of mean number of participants across imputations with partial clearance at Week 8.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Clearance","description":"The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.\n\nPartial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.\n\nThe table shows the percentage of mean number of participants across imputations with partial clearance at Week 4.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction in AK Count in the Treatment Area Compared to Baseline","description":"The percent reduction at Week 8 from baseline was analysed using a negative binomial regression for the AK count at Week 8 with treatment group and pooled sites as factors and baseline count as offset variable (using multiple imputations to account for missing values). The table presents adjusted mean percent reduction at Week 8 from baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"13.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":210},"commonTop":["Application site pain","Application site pruritus","Insomnia","Headache","Eyelid oedema"]}}}